|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Burden of Clostridium difficile infection between 2010 and 2013:Trends and outcomes from an academic center in Eastern Europe显示文摘AIM:To analyze the incidence and possible risk factors in hospitalized patients treated with Clostridium difficile infection(CDI).METHODS:A total of 11751 patients were admitted to our clinic between 1 January 2010 and 1 May2013.Two hundred and forty-seven inpatients were prospectively diagnosed with CDI.For the risk analysis a 1:3 matching was used.Data of 732 patients matched for age,sex,and inpatient care period and unit were compared to those of the CDI population.Inpatient records were collected from an electronic hospital database and comprehensively reviewed.RESULTS:Incidence of CDI was 21.0/1000 admissions(2.1%of all-cause hospitalizations and 4.45%of total inpatient days).The incidence of severe CDI was 12.6%(2.63/1000 of all-cause hospitalizations).Distribution of CDI cases was different according to the unit type,with highest incidence rates in hematology,gastroenterology and nephrology units(32.9,25 and24.6/1000 admissions,respectively) and lowest rates in 1.4%(33/2312) in endocrinology and general internal medicine(14.2 and 16.9/1000 admissions)units.Recurrence of CDI was 11.3%within 12 wk after discharge.Duration of hospital stay was longer in patients with CDI compared to controls(17.6 ± 10.8d vs 12.4 ± 7.71 d).CDI accounted for 6.3%of allinpatient deaths,and 30-d mortality rate was 21.9%(54/247 cases).Risk factors for CDI were antibiotic therapy[including third-generation cephalosporins or fluoroquinolones,odds ratio(OR) = 4.559;P < 0.001],use of proton pump inhibitors(OR = 2.082,P< 0.001),previous hospitaiization within 12 mo(OR = 3.167,P < 0.001),previous CDI(OR = 15.32;P < 0.001),while presence of diabetes mellitus was associated with a decreased risk for CDI(OR = 0.484;P< 0.001).Treatment of recurrent cases was significantly different from primary infections with more frequent use of vancomycin alone or in combination(P < 0.001),and antibiotic therapy duration was longer(P < 0.02).Severity,mortality and outcome of primary infections and relapsing cases did not significantly differ.CONCLUSION:CDI was accounted for significant burden with longer hospitaiization and adverse outcomes.Antibiotic,PPI therapy and previous hospitaiization or CDI were risk factors for CDI. | Zsuzsanna Kurti Barbara D Lovasz Michael D Mandel Zoltan Csima Petra A Golovics Bence D Csako Anna Mohas Lorant Gnczi Krisztina B Gecse Lajos S Kiss Miklos Szathmari Peter L Lakatos | 2015 | World Journal of Gastroenterology2015，21，21： | 6 |
| 2 | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models显示文摘AIM To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma(HCC) patients after liver transplant.METHODS BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein(AFP), Lens culinaris agglutinin-reactive AFP(AFP-L3), and des-gammacarboxyprothrombin(DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios(HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42(1.18-5.00), 1.86(0.98-3.52), and 2.83(1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48(1.15-1.91) and 1.59(1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45(1.06-1.98) and 1.38(1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65,0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant(S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter(S-LAD). | Nicha Wongjarupong Gabriela M Negron-Ocasio Roongruedee Chaiteerakij Benyam D Addissie Essa A Mohamed Kristin C Mara William S Harmsen J Paul Theobald Brian E Peters Joseph G Balsanek Melissa M Ward Nasra H Giama Sudhakar K Venkatesh Denise M Harnois Michael R Charlton Hiroyuki Yamada Alicia Algeciras-Schimnich Melissa R Snyder Terry M Therneau Lewis R Roberts | 2018 | World Journal of Gastroenterology2018，24，12： | 5 |
| 3 | Nat Genet:单基因突变导致过敏性皮炎的发生显示文摘最近,研究者们鉴定出了一类导致神经性皮炎发生的关键基因突变:CARDll。来自美国NIH过敏与传染病研究所的研究者们通过对四个没有血缘关系的患病家庭进行分析,发现了这一导致疾病产生的基因、 | Chi A Ma, Yuan Zhang, Michael A Weinreich, Jonathan J Lyons, Celeste G Nelson, Thomas DiMaggio, Kelly D Stone, Joshua D Milner Jeffrey R Stinson, Elisa Ruffo, Batsukh Dorjbal, Swadhinya Arjunaraja, Kelsey Voss, Andrew L Snow Jordan K Abbott, Pia J Hauk, Paul R Reynolds, Erwin W Gelfand Elisa Ruffo Salomé Glauzy, Natsuko Yamakawa, Eric Meffre Jennifer Stoddard, Julie Niemela, Sergio D Rosenzweig Yu Zhang, Helen F Matthews Joshua J McElwee Nina Jones Alejandro Palma, Matías Oleastro, Emma Prieto, Andrea R Bernasconi, Geronimo Dubra, Silvia Danielian, Jonathan Zaiat, Marcelo A Marti Brian Kim Megan A Cooper Neil Romberg | 2017 | 现代生物医学进展2017，17，27： | 3 |
| 4 | Hospitalized prevalence and 5-year mortality for IBD:Record linkage study显示文摘AIM:To establish the hospitalized prevalence of severe Crohn's disease(CD) and ulcerative colitis(UC) in Wales from 1999 to 2007;and to investigate long-term mortality after hospitalization and associations with social deprivation and other socio-demographic factors.METHODS:Record linkage of administrative inpatient and mortality data for 1467 and 1482 people hospitalised as emergencies for ≥ 3d for CD and UC,respectively.The main outcome measures were hospitalized prevalence,mortality rates and standardized mortality ratios for up to 5 years follow-up after hospitalization.RESULTS:Hospitalized prevalence was 50.1 per 100 000 population for CD and 50.6 for UC.The hospitalized prevalence of CD was significantly higher(P < 0.05) in females(57.4) than in males(42.2),and was highest in people aged 16-29 years,but the prevalence of UC was similar in males(51.0) and females(50.1),and increased continuously with age.The hospital-ized prevalence of CD was slightly higher in the most deprived areas,but there was no association between social deprivation and hospitalized prevalence of UC.Mortality was 6.8% and 14.6% after 1 and 5 years follow-up for CD,and 9.2% and 20.8% after 1 and 5 years for UC.For both CD and UC,there was little discernible association between mortality and social deprivation,distance from hospital,urban/rural residence and geography.CONCLUSION:CD and UC have distinct demographic profiles.The higher prevalence of hospitalized CD in more deprived areas may reflect higher prevalence and higher hospital dependency. | Lori A Button Stephen E Roberts Michael J Goldacre Ashley Akbari Sarah E Rodgers John G Williams | 2010 | World Journal of Gastroenterology2010，16，4： | 3 |
| 5 | Fondaparinux预防老年急性内科患者发生静脉血栓形成的效果与安全性:随机安慰剂对照研究显示文摘目的:观察 Fondaparinux 对具有中高度静脉血栓发生危险的老年急性内科住院患者的抗凝效果与安全性。设计:双盲随机安慰剂对照研究。背景:8个国家的35个中心。参与者:849例≥60岁内科患者,住院原因分别为充血性心力衰竭、慢性肺病合并急性呼吸系统疾患、急性炎症性或感染性疾病,预期至少住院4天以上。干预:2.5 mg Fondaparinux 或安慰剂,每天1次皮下注射,持续6~14天。观察指标:主要指标为静脉血栓形成(治疗后15天内采用双侧静脉造影检查)及有症状的静脉血栓;次要指标为死亡与出血。患者随访时间为1个月。结果:Fondaparinux 治疗组425例患者和安慰剂组414例患者接受了安全性分析(10例未治疗)。644例患者(75.9%)可接受主要指标分析。静脉血栓检出率在 Fondaparinux 治疗组为5.6%(18/321),安慰剂组为10.5%(34/323),相对危险减少46.7%(95% CI 7.7%~69.3%)。安慰剂组5例患者发生有症状的静脉血栓,Fondaparinux治疗组无患者发生有症状的静脉血栓(P=0.029)。两组均有1例(0.2%)患者发生严重出血。随访结束时,安慰剂组、Fondaparinux 治疗组分别死亡25(6.0%)、14(3.3%)例患者。结论:Fondaparinux 可有效预防急性内科老年患者无症状性及有症状的静脉血栓。严重出血几率两组相似。 | Alexander T Cohen Bruce L Davidson Alexander S Gallus Michael R Lassen Martin H Prins Witold Tomkowski Alexander G G Turpie Jan F M Egberts Anthonie W A Lensing 石汉平(译) 王深明(校) | 2006 | 英国医学杂志中文版2006，9，5： | 3 |
| 6 | Mean platelet volume: a useful marker of inflammatory bowel disease activity显示文摘 | Andreas N Kapsoritakis Michael I Koukourakis Aekaterini Sfiridaki Spiros P Potamianos Maria G Kosmadaki Ioannis E Koutroubakis Elias A Kouroumalis | 2001 | The American Journal of Gastroenterology2001，，3： | 2 |
| 7 | Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias显示文摘 | Steven L Higgins John D Hummel Imran K Niazi Michael C Giudici Seth J Worley Leslie A Saxon John P Boehmer Michael B Higginbotham Teresa De Marco Elyse Foster Patrick G Yong | 2003 | Journal of the American College of Cardiology2003，，8： | 2 |
| 8 | Soil pits as a simple design aid for subsurface drip irrigation systems显示文摘 | Michael A B Bruce G S David G B | 2003 | Irrig Sci2003，22，： | 1 |
| 9 | Pepsin-digested peanut contains T-cell epitopes but no IgE epitopes显示文摘 | HONG S J MICHAEL J G FEHRINGER A | 1999 | Journal of Allergy and Clinical Immunology1999，104，2： | 1 |
| 10 | Criteria for the Assessment of Reliability Models显示文摘 | MICHAEL G P ANAND A S | 1997 | IEEE Transaction on Components1997，20，3： | 1 |
| 11 | Highly sensitive immunoassay based on a monoclonal antibody specific for microcystins 显示文摘 | Zeck A Eikenberg A Weller Michael G | 2001 | Analytica Chimica Acta2001，441，1： | 1 |
| 12 | Hypothermia during head and neck surgery 显示文摘 | Agrawal N Duane A S Michael E G | 2003 | Laryngoscope2003，113，： | 1 |
| 13 | Neum protective proper- ties and mechanisms of erythropoietin in vitro and in vivo ex- perimental models for hypoxia/ischemia显示文摘 | Michael A van der K Floris G | 2008 | Brain Research Re- views2008，59，1： | 1 |
| 14 | COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease显示文摘 | Wayne A Ray C Michael Stein James R Daugherty Kathi Hall Patrick G Arbogast Marie R Griffin | 2002 | The Lancet2002，，9339： | 1 |
| 15 | A contactless biometric system using multiple hand features 显示文摘 | MICHAEL G K O CONNIE T TEOH A B J | 2012 | Journal of Visual Communication and Image Representation2012，23，7： | 1 |
| 16 | Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins显示文摘 | David R Borchelt Tamara Ratovitski Judy van Lare Michael K Lee Vicki Gonzales Nancy A Jenkins Neal G Copeland Donald L Price Sangram S Sisodia | 1997 | Neuron1997，，4： | 1 |
| 17 | Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial显示文摘 | John R Teerlink Gad Cotter Beth A Davison G Michael Felker Gerasimos Filippatos Barry H Greenberg Piotr Ponikowski Elaine Unemori Adriaan A Voors Kirkwood F Adams Maria I Dorobantu Liliana R Grinfeld Guillaume Jondeau Alon Marmor Josep Masip Peter S Pang | 2013 | The Lancet . 2013 (9860)2013，，9860： | 1 |
| 18 | The Reliability Physics Approach to Failure Prediction Modeling显示文摘 | MICHAEL G PECHT A | 1990 | Quality and Engineering International1990，，6： | 1 |
| 19 | A closed chamber CO2 flux method for estimating marsh productivity 显示文摘 | William J S Alan J G Michael A C | 1998 | Aquatic Botany1998，62，： | 1 |
| 20 | Improved resolution methods for (R,R)-and (S,S)-cyclohexane-1,2-diamine and (R)-and (S)-BINOL显示文摘 | Hans-Jorg Schanz Michael A Linseis Declan G Gilheany | 2003 | Tetrahedron:Asymmetry2003，14，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员